10th March, 2023 (Friday)

Pre-congress: Industry Sponsored Dinner Symposium: Jansen
Chairperson: Tho Lye Mun
Time Topic Speaker
18.00-18.15 Registration
18.15-18.20 Welcoming speech Lim Yee Pin
18.20-18.25 Opening remark Tho Lye Mun
18.25-18.45 The knowns unknowns John Low Seng Hooi
18.45-19.15 The new weapon Cho Byoung Chul (Korea)
19.15-20.00 Case study & panel discussion Tho Lye Mun
Panellists:
Cho Byoung Chul (Korea)
Liam Chong Kin
Adlinda binti Alip
Pathmanathan Rajadurai
John Low Seng Hooi
20.00-20.15 Product Launching 
20.15-21.30 Dinner

Day 1: 11th March, 2023 (Saturday)

Time Topic Speaker
08.00-08.20 Registration 
08.20-08.30 Welcoming remarks Tho Lye Mun
Symposium 1: Challenges in lung cancer diagnosis and staging 
Chairperson: Arvindran Alaga/Andrea Ban Yu-Lin
08.30-08.50 Staging of lung cancer - Radiologist perspective Zuhanis Abdul Hamid
08.50-09.10 Staging of lung cancer - Pulmonologist perspective Hema Yamini Devi
09.10-09.30 Biomarkers testing in Malaysia? How to choose Roziana Ariffin
09.30-09.50 NGS in lung cancer – choosing the right test Aaron Tan (Singapore)
09.50-10.30 Industry Sponsored Tea Symposium: AstraZeneca 
Chairperson: Tho Lye Mun
Complementing Trial Results with Real World Practice: A crossover from FLAURA to REIWA
Tan Chih Kiang
10.30-11.00 Tea Break
Symposium 2: Early stage and locally invasive lung cancer
Chairperson: Lim Yueh Ni/ Benedict Dharmaraj Retna Pandian
11.00-11.20 Contemporary management of early-stage lung cancer - a thoracic surgical perspective Anand Sachithanandan
11.20-11.40 Approach to borderline operable NSCLC Soon Sing Yang
11.40-12.00 SBRT in early lung cancer and oligo-metastasis Jasmin Loh Pei Yuin
12.00-13.00 Industry Sponsored Lunch Symposium: Roche
Chairperson: Liam Chong Kin
Changing landscape in early stage Lung cancer with Immunotherapy: What’s new?
Toh Chee Keong (Singapore)
13.00-14.00 Lunch Break
Symposium 3: Small cell lung cancer and other neuroendocrine tumour 
Chairperson: Ibtisam Muhamad Nor/ Azlina Shamsudin
14.00-14.20 New approaches in SCLC Malwinder Singh Sandhu
14.20-14.40 Role of surgery in SCLC Narasimman Sathiamurthy
14.40-15.00 Carcinoid and other lung neuroendocrine tumour: An update  Teo Yin Keong
15.00-15.40 Industry Sponsored Tea Symposium: Pfizer
Chairperson: Liam Chong Kin
Let’s tALK about the Evolving ALK+ NSCLC Treatment Landscape
John Low Seng Hooi
15.40-16.10 Tea Break
Symposium 4: Advanced NSCLC without driver mutation
Chairperson: John Low Seng Hooi/Syazatul Syakirin 
16.10-16.30 Advanced NSCLC without driver mutation: Treatment Landscape in Malaysia Nurhayati Mohd Marzuki
16.30-16.50 Best first line regime for advanced NSCLC without driver mutation Ahn Myung Ju (Korea)
16.50-17.10 Best second line regime after chemotherapy and immunotherapy combination Tan Jiunn Liang
17.10-18.10 Industry Sponsored Dinner Symposium: MSD
Chairperson: Tan Jiunn Liang
Deep Diving into the Emerging Evidence of ICI and chemotherapy for PDL-1 negative expression.
Ahn Myung Ju (Korea)
18.10-20.00 Dinner

Day 2: 12th March, 2023 (Sunday)

Time Topic Speaker
08.00-08.30 Registration 
Symposium 5: Targeted therapy in Advanced NSCLC
Chairperson: Irfhan Hyder/Marfuah Nik Eezamuddeen
08.30-08.50 Real world EGFR and ALK data: Malaysian Lung Cancer Registry Poh Mau Ern
08.50-09.10 New targets beyond EGFR, ALK and ROS1 Liam Chong Kin
09.10-09.30 What Next? Options after Progression on EGFR TKIs Azza Omar
09.30-09.50 Approaches to uncommon EGFR mutation Cho Byoung Chul (Korea)
09.50-10.30 Industry Sponsored Tea symposium: Boehringer Ingelheim
Chairperson: Yap Beng Khiong
Optimizing sequential treatment outcomes in EGFR mutation-positive NSCLC Patients
Muthukkumaran Thiagarajan
10.30-11.00 Tea
Symposium 6: Palliative Care and Management of Symptoms and Common Adverse Events
Chairperson: Aisya Natasya Musa/Leong Siew Mooi
11.00-11.20 Palliative Radiotherapy in the Era of Targeted and Immunotherapy Daniel Gan Eng Hwee
11.20-11.40 Management of life threatening irAE  Aaron Tan (Singapore)
11.40-12.00 Palliation in the era of so many treatment possibilities – how to know when to stop? Richard Lim Boon Leong
12.00-13.00 Industry Sponsored Lunch Symposium: Takeda
Chairperson: Ho Gwo Fuang
Treatment selection of newly diagnosed ALK+ NSCLC with baseline brain metastases
Min Hee Hong  (Korea)
13.00-14.00 Lunch
14.00-15.30 Multidisciplinary Discussion 
Chairperson: How Soon Hin / Tan Jiunn Liang

Panelists:
Tho Lye Mun
Liam Chong Kin
Soon Sing Yang
Aaron Tan (Singapore)
Ho Gwo Fuang

15.30-16.10 Industry Sponsored Tea Symposium: Amgen
Chairperson: Pang Yong Kek
Unmet need in KRAS G12C
Alfredo Addeo (Switzerland)
16.10-16.30 Closing remarks & lucky draw How Soon Hin
16.10-17.00 Tea